
  
    
      
        
        There_EX are_VBP 300_CD million_CD cases_NNS of_IN malaria_NN each_DT year_NN worldwide_NN ,_, causing_VBG one_CD million_CD deaths_NNS ._.
        Around_IN 90_CD %_NN of_IN these_DT deaths_NNS occur_VBP in_IN Africa_NNP ,_, mostly_RB in_IN young_JJ children_NNS ._. One_CD of_IN the_DT greatest_JJS
        challenges_NNS facing_VBG Africa_NNP in_IN the_DT fight_NN against_IN malaria_NN is_VBZ drug_NN resistance_NN ;_: resistance_NN to_TO
        chloroquine_NN (_( CQ_NNP )_) ,_, the_DT cheapest_JJS and_CC most_RBS widely_RB used_VBN antimalarial_NN ,_, is_VBZ common_JJ throughout_IN
        Africa_NNP ,_, and_CC resistance_NN to_TO sulfadoxine-pyrimethamine_JJ (_( SP_NNP )_) ,_, the_DT first-developed_JJ and_CC least_JJS
        expensive_JJ alternative_NN to_TO CQ_NNP ,_, is_VBZ also_RB increasing_VBG in_IN eastern_JJ and_CC southern_JJ Africa_NNP ._. These_DT
        trends_NNS have_VBP forced_VBN many_JJ countries_NNS to_TO change_VB their_PRP$ treatment_NN policies_NNS and_CC use_NN more_RBR expensive_JJ
        drugs_NNS ,_, including_VBG drug_NN combinations_NNS that_WDT will_MD hopefully_RB slow_VB the_DT development_NN of_IN resistance_NN ._.
        One_CD avenue_NN of_IN research_NN is_VBZ to_TO identify_VB combinations_NNS that_WDT minimize_VB gametocyte_NN emergence_NN in_IN
        treated_VBN cases_NNS and_CC prevent_VB selective_JJ transmission_NN of_IN parasites_NNS resistant_JJ to_TO any_DT of_IN the_DT
        partner_NN drugs_NNS ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP Colin_NNP Sutherland_NNP and_CC colleagues_NNS tested_VBD two_CD leading_VBG
        combination_NN therapies_NNS in_IN children_NNS with_IN uncomplicated_JJ malaria_NN ._. One_CD regimen_NN was_VBD an_DT
        artemisinin-based_JJ combination_NN consisting_VBG of_IN artemether_NN and_CC lumefantrine_NN (_( co-artemether_JJ ,_,
        trade_NN names_NNS CoArtem_NNP and_CC Riamet_NNP )_) ._. The_DT other_JJ was_VBD a_DT combination_NN of_IN CQ_NNP and_CC SP—currently_NNP under_IN
        consideration_NN in_IN several_JJ African_JJ countries_NNS ,_, largely_RB due_JJ to_TO its_PRP$ low_JJ cost_NN ._. In_IN this_DT
        randomized_JJ ,_, controlled_VBN trial_NN ,_, 497_CD children_NNS with_IN acute_JJ uncomplicated_JJ falciparum_NN malaria_NN were_VBD
        given_VBN either_CC a_DT combination_NN of_IN CQ_NNP and_CC SP_NNP or_CC six_CD doses_NNS of_IN co-artemether_JJ (_( 91_CD received_VBD CQ_NNP /_NN SP_NNP
        and_CC 406_CD received_VBD co-artemether_JJ )_) ,_, and_CC their_PRP$ blood_NN was_VBD tested_VBN for_IN infectivity_NN to_TO mosquitoes_NNS
        seven_CD days_NNS after_IN treatment_NN ._. During_IN follow_VB up_RB at_IN seven_CD ,_, 14_CD ,_, and_CC 28_CD days_NNS the_DT team_NN found_VBD that_IN
        children_NNS treated_VBN with_IN co-artemether_JJ were_VBD significantly_RB less_RBR likely_JJ to_TO carry_VB gametocytes_NNS in_IN
        their_PRP$ blood_NN than_IN children_NNS treated_VBN with_IN CQ_NNP and_CC SP—_NNP 7_CD ._. 9_CD %_NN compared_VBN with_IN 48_CD ._. 8_CD %_NN ._.
        Altogether_RB ,_, the_DT six-dose_JJ regimen_NN of_IN co-artemether_JJ was_VBD highly_RB effective_JJ at_IN reducing_VBG the_DT
        prevalence_NN and_CC duration_NN of_IN gametocyte_NN carriage_NN ._. The_DT numbers_NNS of_IN gametocytes_NNS and_CC the_DT
        infectiousness_NNS to_TO mosquitoes_NNS at_IN day_NN 7_CD were_VBD also_RB reduced_VBN compared_VBN to_TO a_DT combination_NN of_IN CQ_NNP and_CC
        SP_NNP ,_, said_VBD the_DT authors_NNS ._. Other_JJ studies_NNS have_VBP already_RB shown_VBN the_DT potential_NN of_IN co-artemether_JJ
        combination_NN therapy_NN to_TO both_DT cure_NN malaria_NN and_CC reduce_VB gametocyte_NN carriage_NN ,_, acknowledged_VBD the_DT
        authors_NNS ._. However_RB ,_, this_DT study_NN is_VBZ the_DT first_JJ to_TO demonstrate_VB the_DT treatment_NN 's_POS potential_JJ to_TO
        markedly_RB reduce_VB the_DT infectiousness_NNS of_IN patients_NNS to_TO mosquitoes_NNS ,_, and_CC has_VBZ done_VBN so_RB in_IN a_DT
        sub-_NN Saharan_NNP African_JJ setting_NN with_IN highly_RB seasonal_JJ transmission_NN and_CC where_WRB asymptomatic_JJ
        infections_NNS are_VBP common_JJ ._.
        Do_VBP the_DT results_NNS mean_VBP co-artemether_JJ should_MD be_VB introduced_VBN as_IN a_DT first-line_JJ treatment_NN for_IN
        malaria_NN in_IN Africa_NNP ?_. The_DT authors_NNS are_VBP hesitant_JJ and_CC suggest_VBP there_EX might_MD be_VB compliance_NN issues_NNS
        with_IN the_DT six-dose_JJ regimen_NN ._. The_DT requirement_NN of_IN oily_JJ food_NN for_IN adequate_JJ absorption_NN might_MD also_RB
        lead_VB to_TO inadequate_JJ drug_NN levels_NNS in_IN the_DT blood_NN of_IN many_JJ treated_VBN individuals_NNS ._.
        The_DT authors_NNS suggest_VBP that_IN co-artemether_JJ as_IN a_DT first-line_JJ treatment_NN is_VBZ not_RB likely_JJ to_TO reduce_VB
        overall_JJ transmission_NN of_IN 
        Plasmodium_NNP falciparum_NN within_IN the_DT community_NN but_CC rather_RB would_MD
        reduce_VB selective_JJ transmission_NN of_IN resistant_JJ parasites_NNS in_IN treated_VBN patients_NNS ._. Hence_RB ,_,
        co-artemether_JJ could_MD have_VB a_DT public_JJ health_NN benefit_NN by_IN reducing_VBG the_DT impact_NN of_IN drug_NN
        resistance_NN ._.
      
    
  
